| Intravenous immunoglobulin therapy for neurological disorders. | |
| | |
MedLine Citation:
|
PMID: 19966877 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: To determine the extent to which the use of intravenous human immunoglobulin for neurological conditions complied with the guidelines of the Australian Health Minister's Advisory Council. METHODS: Patients treated with intravenous immunoglobulin in Otago over a 5.5-year period were identified from the records of the New Zealand Blood Service and the hospital files were reviewed. RESULTS: 200 patients received immunoglobulin therapy, of whom 57 had neurological conditions: myasthenia gravis, (15.8%), Guillain-Barre syndrome (36.8%), multiple sclerosis (10.5%), chronic inflammatory demyelinating polyneuropathy (17.5%), inclusion body myositis (7%), polymyositis (1.7%), miscellaneous disorders (stiff person syndrome, diabetic amyotrophy, neuropathy associated with paraproteinaemia, and hereditary neuropathy with liability to pressure palsies) (10.5). Thirty-one percent of the immunoglobulin was used in 27% of the patients for disorders lacking convincing evidence of benefit according to the guidelines of the Australian Health Minister's Advisory Council. These were multiple sclerosis, inclusion body myositis, and miscellaneous neuropathies. Good response occurred most often in patients with myasthenia gravis, Guillain-Barre syndrome, multiple sclerosis, and chronic inflammatory demyelinating polyneuropathy. CONCLUSIONS: Intravenous immunoglobulin was frequently used for indications not recommended by the Australian Health Minister's Advisory Council guidelines. However guidelines vary internationally, and there is a paucity of controlled studies to guide management of some uncommon conditions. |
| | |
Authors:
|
Catriona Harkins; Graeme Hammond-Tooke; James Faed |
Related Documents
:
|
10833897 - Fundic gland polyps: a still elusive entity on the eve of the year 2000. 1953537 - Poems syndrome, osteosclerotic myeloma and castleman's disease: a case report. 2144237 - Opercular syndrome without opercular lesions: foix-chavany-marie syndrome in progressiv... 3044117 - The prenatal sonographic diagnosis of lethal multiple pterygium syndrome: a heritable c... 2634137 - A case of incomplete digeorge syndrome associated with partial monosomy 22q11.1 due to ... 21273057 - Young age and a positive family history of colorectal cancer are complementary selectio... |
Publication Detail:
|
Type: Journal Article Date: 2009-10-30 |
Journal Detail:
|
Title: The New Zealand medical journal Volume: 122 ISSN: 1175-8716 ISO Abbreviation: N. Z. Med. J. Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-12-07 Completed Date: 2010-01-06 Revised Date: 2010-10-22 |
Medline Journal Info:
|
Nlm Unique ID: 0401067 Medline TA: N Z Med J Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 41-6 Citation Subset: IM |
Affiliation:
|
Glasgow Royal Infirmary, Glasgow, Scotland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Child Female Guideline Adherence* Humans Immunoglobulins, Intravenous* / administration & dosage, adverse effects Male Medical Audit* Middle Aged Nervous System Diseases / therapy* New Zealand Treatment Outcome Utilization Review |
| Chemical | |
Reg. No./Substance:
|
0/Immunoglobulins, Intravenous |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Travelling surgeons: a clinical audit of laparoscopic cholecystectomy procedures in Northland, New Z...
Next Document: Temporal lobe resection for refractory temporal lobe epilepsy at Auckland Hospital.